NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $2.75 +0.09 (+3.38%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.73 -0.02 (-0.62%) As of 06/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rocket Pharmaceuticals Stock (NASDAQ:RCKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.66▼$2.8350-Day Range$2.60▼$3.9152-Week Range$2.40▼$5.45Volume2.44 million shsAverage Volume2.38 million shsMarket Capitalization$300.27 millionP/E RatioN/ADividend YieldN/APrice Target$8.44Consensus RatingHold Company Overview Rocket Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms. The company’s pipeline comprises multiple product candidates in various stages of development. Lead programs such as RP-L102 for Fanconi anemia and RP-L301 for leukocyte adhesion deficiency type I have advanced into clinical trials, where Rocket is evaluating safety and preliminary efficacy. Preclinical efforts include gene therapy candidates for Danon disease and other lysosomal storage disorders. Rocket leverages in-house manufacturing capabilities alongside strategic partnerships to support its clinical and potential commercial supply needs. Founded in 2015 as a spin-out from academic research institutions, Rocket Pharmaceuticals established its headquarters in New York City. Since inception, the company has expanded its research and development infrastructure to include state-of-the-art manufacturing and clinical trial support facilities. Its management team draws upon expertise in gene therapy development, regulatory strategy and rare disease commercialization to guide programs from laboratory to the clinic. Rocket Pharmaceuticals serves patient populations primarily in the United States and collaborates with international academic and clinical centers to advance global trial enrollment. The company’s efforts are underpinned by partnerships with nonprofit organizations and academic research groups dedicated to rare disease advocacy, reflecting a commitment to bringing transformative therapies to underserved communities worldwide.AI Generated. May Contain Errors. Read More Rocket Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreRCKT MarketRank™: Rocket Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 573rd out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingRocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 3 sell ratings.Upside PotentialRocket Pharmaceuticals has a consensus price target of $8.44, representing about 207.1% upside from its current price of $2.75.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Rocket Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.16) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.12% of the float of Rocket Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.52.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 7.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentRocket Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest7 people have searched for RCKT on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows6 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $275,307.00 in company stock.Percentage Held by Insiders21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKT Stock News HeadlinesRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 MillionJune 12 at 7:00 AM | businesswire.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 13 at 1:00 AM | Reagan Gold Group (Ad)Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Hold" by BrokeragesJune 7, 2026 | americanbankingnews.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 5, 2026 | seekingalpha.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below 200-Day Moving Average - Should You Sell?June 3, 2026 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) CEO Gaurav Shah Sells 55,684 SharesMay 27, 2026 | insidertrades.comInsider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of StockMay 15, 2026 | insidertrades.comSee More Headlines RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $3.51 on January 1st, 2026. Since then, RCKT shares have decreased by 21.7% and is now trading at $2.75. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.01. When did Rocket Pharmaceuticals IPO? Rocket Pharmaceuticals (RCKT) raised $94 million in an initial public offering on Friday, February 6th 2015. The company issued 6,700,000 shares at a price of $13.00-$15.00 per share. Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' top institutional shareholders include Maverick Capital Ltd. (3.27%), Renaissance Technologies LLC (0.58%), Bank of America Corp DE (0.58%) and ADAR1 Capital Management LLC (0.40%). Insiders that own company stock include Gaurav Shah, Martin Wilson, Gotham Makker, Sarbani Chaudhuri, Jonathan David Schwartz, Aaron Ondrey, David P Southwell, David P Southwell, John Militello, Mark Andrew White, Elisabeth Bjork and Kinnari Patel. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), Humana (HUM), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2026Today6/13/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 4 days ago, RCKT's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKT CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees240Year Founded2018Price Target and Rating Average Price Target for Rocket Pharmaceuticals$8.44 High Price Target$16.00 Low Price Target$3.00 Potential Upside/Downside+207.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$223.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.61% Return on Assets-58.63% Debt Debt-to-Equity Ratio0.08 Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book1.07Miscellaneous Outstanding Shares109,190,000Free Float85,936,000Market Cap$300.27 million OptionableOptionable Beta0.48 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RCKT) was last updated on 6/13/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
